COMPANY

Crystalys Therapeutics

Keywords: gout Tophaceous Gout Dotinurad

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series B · $130M · announced Jul 27, 2026 Company release ↗
Source quote
- Jul 27, 2026 · Company release ↗
  “Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing”
Raise Series A · $205M · announced Oct 1, 2025 Company release ↗
Source quote
- Oct 1, 2025 · Company release ↗
  “Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing”

Raises announced in these releases: $335M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jul 27, 2026 Raise Series B · $130M source ↗
Jul 22, 2026 Raise Private equity round — Series B: $130M (total, as published), announced Jul 22, 2026. Source: company's own press page. source ↗
May 8, 2026 Trial start 2: A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants source ↗
Oct 1, 2025 Raise Series A · $205M source ↗
Sep 30, 2025 Raise Private equity round: $205M (total, as published), announced Sep 30, 2025. Source: company's own press page. source ↗
Aug 4, 2025 Trial start Phase 3: A Study of Dotinurad Versus Allopurinol in Tophaceous Gout source ↗
Aug 1, 2025 Trial start Phase 3: A Study of Dotinurad Versus Allopurinol in Participants With Gout source ↗

2027-07 (ESTIMATED) · 2 · A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants · NCT07535034
Nov 29, 2027 (ESTIMATED) · Phase 3 · A Study of Dotinurad Versus Allopurinol in Participants With Gout · NCT07089875
Dec 31, 2027 (ESTIMATED) · Phase 3 · A Study of Dotinurad Versus Allopurinol in Tophaceous Gout · NCT07089888

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $335.0M. Last 2 years.

Jul 22, 2026 Private equity round — Series B: $130M (total, as published), announced Jul 22, 2026. Source: company's own press page. source ↗
Sep 30, 2025 Private equity round: $205M (total, as published), announced Sep 30, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07089875	A Study of Dotinurad Versus Allopurinol in Participants With Gout	Phase 3	Recruiting	Aug 1, 2025	Nov 29, 2027 (estimated)
NCT07089888	A Study of Dotinurad Versus Allopurinol in Tophaceous Gout	Phase 3	Recruiting	Aug 4, 2025	Dec 31, 2027 (estimated)
NCT07535034	A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants	2	Recruiting	May 8, 2026	2027-07 (estimated)